Screener
Spyre Therapeutics, Inc. SYRE Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total other (expense) income | (23,364) | 8,779 |
| Loss before income tax expense | (69,005) | (44,788) |
| Income tax benefit | — | 15 |
| Net loss | $(69,005) | $(44,773) |
| Net loss per share, basic and diluted, Series A Preferred Stock | $(29.66) | $(23.95) |
| Weighted-average Series A non-voting convertible preferred stock outstanding, basic and diluted | 346,045 | 346,045 |
| Net loss per share, basic and diluted, Series B Preferred Stock | $(29.66) | $(23.95) |
| Weighted-average Series B non-voting convertible preferred stock outstanding, basic and diluted | 16,667 | 16,667 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s net income?
- Spyre Therapeutics, Inc. (SYRE) reported net income of -$69.01M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s net income changed year-over-year?
- Spyre Therapeutics, Inc.'s net income decreased by 54.1% year-over-year, from -$44.77M to -$69.01M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s net income has grown at a 23.9% compound annual growth rate (CAGR), from -$65.8M to -$155.2M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Spyre Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude